| ID Source | ID |
|---|---|
| PubMed CID | 23668196 |
| CHEMBL ID | 1365278 |
| CHEBI ID | 9177 |
| SCHEMBL ID | 37482 |
| MeSH ID | M0331377 |
| Synonym |
|---|
| MLS002695906 |
| smr001562102 |
| CHEBI:9177 , |
| sodium 7-deoxycholate |
| deoxycholate sodium |
| sodium 3alpha,12alpha-dihydroxy-5beta-cholan-24-oate |
| sodium desoxycholate |
| desoxycholate sodium |
| AKOS002391107 |
| sodium 3-alpha,12-alpha-dihydroxy-5-beta-cholan-24-oate |
| 3,12-dihydroxy-cholan-24-oic acid monosodium salt, (3-alpha,5-beta,12-alpha)- |
| 5-beta-cholan-24-oic acid, 3-alpha,12-alpha-dihydroxy-, sodium salt |
| cholan-24-oic acid, 3,12-dihydroxy-, monosodium salt, (3alpha,5beta,12alpha)- |
| ccris 655 |
| cholan-24-oic acid, 3,12-dihydroxy-, monosodium salt, (3-alpha,5-beta,12-alpha)- |
| natrium-3-alpha,12-alpha-dihydroxycholanat [german] |
| 3-alpha,12-alpha-dihydroxy-5-beta-cholan-24-oic acid sodium salt |
| na-desoxycholat [german] |
| sodium deoxycholic acid |
| einecs 206-132-7 |
| deoxycholic acid, sodium salt |
| dihydroxy 3-12 cholanate de na [french] |
| deoxycholic acid sodium salt |
| NCGC00091038-01 |
| 302-95-4 |
| sodium deoxycholate |
| sodium deoxycholate, >=97% (titration) |
| sodium (3alpha,5beta,12alpha)-3,12-dihydroxycholan-24-oate |
| sodium deoxycholate, bioxtra, >=98.0% (dry matter, nt) |
| NCGC00258450-01 |
| tox21_200896 |
| cas-302-95-4 |
| dtxsid5033389 , |
| dtxcid3013389 |
| tox21_111066 |
| natrium-3-alpha,12-alpha-dihydroxycholanat |
| dihydroxy 3-12 cholanate de na |
| unii-436ls6u35y |
| na-desoxycholat |
| nsc 681065 |
| 436ls6u35y , |
| sodium desoxycholate [ii] |
| 3-.alpha.,12-.alpha.-dihydroxy-5-.beta.-cholan-24-oic acid sodium salt |
| sodium deoxycholate [inci] |
| BP-31018 |
| AKOS017345123 |
| SCHEMBL37482 |
| CHEMBL1365278 |
| Q-200935 |
| sodiumdeoxycholate |
| cholan-24-oic acid, 3,12-dihydroxy-, monosodium salt, (3a,5b,12a)- |
| CS-8046 |
| HY-N0593A |
| AC-24206 |
| mfcd00064139 |
| deoxycholic acid sodium salt, for electrophoresis |
| sodium deoxycholate, suitable for manufacturing of diagnostic kits and reagents |
| sodium deoxycholate, vetec(tm) reagent grade, >=97% |
| sodium (4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate |
| 3,12-dihydroxy-cholan-24-oic acid monosodium salt, (3-alpha,5-beta,12-alpha)- (9ci) |
| Q25474151 |
| sodium;(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate |
| sodium;(4r)-4-[(3r,5r,10s,12s,13r,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| bile acid salt | A salt of a bile acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 15.8489 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 89.1251 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 34.7099 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 38.3914 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 38.3914 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| TDP1 protein | Homo sapiens (human) | Potency | 33.4983 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 49.0290 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 28.2587 | 0.0002 | 21.2231 | 8,912.5098 | AID1259247; AID743035; AID743042; AID743054; AID743063 |
| progesterone receptor | Homo sapiens (human) | Potency | 69.2554 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 49.6323 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720692 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 32.7263 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 67.9355 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 47.3305 | 0.3758 | 27.4851 | 61.6524 | AID743220; AID743239 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 31.8257 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078; AID743079 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 24.7704 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 26.8448 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743140 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 55.1427 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.2660 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8777 | 0.0016 | 28.0151 | 77.1139 | AID1224895; AID1259385 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 55.1427 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 54.3438 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 57.0298 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 64.0707 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743219 |
| geminin | Homo sapiens (human) | Potency | 0.0731 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 70.1447 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 42.1632 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutathione S-transferase omega-1 | Homo sapiens (human) | IC50 (µMol) | 1,020.0000 | 0.0280 | 1.6040 | 4.6000 | AID1384567 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1384567 | Inhibition of human GSTO1-1 by MMA (V) reductase assay | 2018 | Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17 | Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.39) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||